October 2021

Khuba calls on doctors and health workers to promote the use of generic drugs

by Joan J. Dean on October 29, 2021

Calling on doctors, health workers and ASHAs to promote the use of generic drugs, Union Minister of State for Chemicals and Fertilizers Bhagwanth Khuba said on Friday that the drugs significantly reduce the cost drugs for people.

Speaking at Janaushadhi Mitra Sammelan, Mr. Khuba said that 145 generic drugs are available at Janaushadi Kendras and these drugs are sold at a cost less than 70% to 90% of the cost of brand name drugs. “By making generic drugs available at an affordable price, Prime Minister Narendra Modi has helped people save on drugs to a great extent,” he said.

Citing an example, Mr Khuba said that the brand name drug Atorvastatin, which is prescribed to lower cholesterol, costs 12 per pill, while the same drug is available at 0.98 paise at a generic pharmacy.

The Union Minister of State urged the government and private doctors to prescribe more generic drugs. He said that Anganwadi workers and ANMs should educate doctors and the population about generic drugs. He also called on the operators of Janaushadhi kendra to carry out activities to raise awareness about the availability of medicines for hypertension, diabetes and chronic diseases, which are regularly consumed by many people.

During the interaction with Mr. Khuba, some of the representatives of the 82 Jananushadhi Kendra in Dakshina Kannada pointed out the poor quality of some of the drugs provided. Another Kendra operator raised the issue of getting Suvidha sanitary napkins for the price of 1, for which there is good demand. A doctor, who has a Janaushadhi Kendra near his hospital in Puttur, expressed the need for more essential drugs in the kendras.

Khuba said the ministry was taking action to address issues related to the quality and supply of medicines. “It’s an ongoing process and we are responding to your concerns. We sincerely believe in making quality essential medicines available to the population, ”he said. Changes are being made to the Janushadhi Sugam app to give people a clear idea of the drugs available in the kendras, he said.

MP Nalin Kumar Kateel and MP for Mangaluru City South D. Vedavyas Kamath spoke.

Mr. Khubha and Mr. Kateel presented the Janaushadhi Prabhuddi Prize to the Udupi District Administration, the district being the first among Karnataka districts in terms of sales of generic drugs. The two men also presented Janaushadhi Mitra Awards to seven people, including three doctors, for the promotion of Janaushadhi Kendras.

Medical products

University of Toronto Testing Laboratory

by Joan J. Dean on October 25, 2021

I3 Biomedical laboratories

Photo credit: I3 BioMedical Inc.

MIRABEL, Quebec, October 26, 2021 (GLOBE NEWSWIRE) – i3 BioMedical Inc. (www.i3biomedical.com) achieves the fastest and most efficient “kill rate” of SARS-CoV-2. TrioMed sets the standard for unparalleled superiority in active protection worldwide.

Virucidal technology developed by i3 BioMedical Inc. has been confirmed to deactivate over 99.9% of SARS-CoV-2 – the virus that causes COVID-19 – on the exterior surface of TrioMed Active Medical products (including mask) within 5 minutes after 8 hours of sham use, based on independent virological testing at the University of Toronto.

The scientists, led by Professor Scott Gray-Owen of the Department of Molecular Genetics at the University of Toronto’s Temerty School of Medicine, used the faculty’s high-tech level three (CL3) containment lab to test the effectiveness of the protective layer of TrioMed Active Medical products.

“Our tests confirmed that the TrioMed Active technology deactivates over 99.9% of SARS-CoV-2 at the current fastest test time point of 5 minutes when applying the virus after 8 hours of using the mask, ”says Gray-Owen, who has no affiliation with the company or its employees.

“The TrioMed Active material was subjected to an exceptionally demanding protocol for a period of 8 hours in our laboratories representing extreme conditions of use for face masks, gowns and similar medical products, before being sent to the University, ”said Mohammed Belhaj, president of Atlas. Pharma inc. (Health Canada registration # 102041-A)

“For more than a decade, TrioMed technology has offered the highest level of protection against many microorganisms to users around the world. For antimicrobial medical products, the ‘kill rate’ parameter is essential to provide true protection: a ‘kill rate’ of 30 minutes to hours does not sufficiently protect the wearer, meaning that viruses remain infectious throughout. period. Only an antimicrobial ‘kill speed’ of up to 5 minutes provides TRUE protection, ”said Pierre Jean Messier, Executive Chairman of i3 BioMedical Inc.

TrioMed Active products have been systematically used and tested against numerous pathogenic bacteria and viruses for over 10 years with consistent results of killing (deactivating) over 99.9% within 5 minutes of all microbes tested.

TrioMed Active provides the benchmark of unmatched efficacy in active anti-bacterial and anti-viral protection technology

TrioMed Active Technology, visit www.triomed.com or send an email to [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fea5dd10-6960-4e9f-bc48-067c1340986c

Generic drugs

The pros and cons of generic drugs explored

by Joan J. Dean on October 24, 2021

A patient who takes lorazepam (a generic version of Ativan) for her anxiety tells me that her medications have not worked as before in the past few months. She can’t identify what’s wrong, but she doesn’t like how it makes her feel. She thinks to herself that the pharmacy must have changed providers, but that shouldn’t really matter, because aren’t all generics supposed to work the same? Zoom in on some of the often overlooked facts about generic drugs.

What are generic drugs?

When a new drug is approved, it is patented for up to 20 years, giving the original manufacturer time and space in the market to recoup some of the costs of research and discovery. When the patent expires, other companies are allowed to manufacture a similar drug (a generic) that is “bioequivalent”, which means that it delivers the same active ingredient to the same part of the body, over the same length of time. than the original drug.

Are Generic Drugs Less Expensive?

The cost of producing a generic is much cheaper than the original, and competition from several manufacturers drives the price down even further. The price difference is greatest for drugs whose patents have long expired and whose market is dominated by generics. For example, the average monthly retail price of lorazepam is $ 24, compared to $ 1,386 for Ativan.

Insurance companies encourage patients to choose generics with a lower co-payment and sometimes categorically refuse to cover brand-name drugs. On the other hand, pharmaceutical companies are offering coupons and discounts to offset the direct cost of brand name drugs in order to maintain their market share.

Following:Health Matters: Let the Data Talk – Follow-up Questions on COVID Vaccines

Who takes the generic drugs?

Almost everybody. In 2020, 90% of all prescriptions in the United States were filled with generics, and that number has steadily increased since the Drug Price Competition and Patent Term Restoration Act of 1984. (also known as the Hatch-Waxman Act) opened the regulatory valve. in the manufacture of generic drugs. It is estimated that the use of generic drugs has saved Americans $ 313 billion a year in health care costs.

Are there any downsides to generics?

Quality control is a major concern. Companies reduce their costs by outsourcing production; the vast majority of generic drugs in America are made in India and China, while others rely on raw ingredients from these countries. Factories are not as frequently inspected by the FDA as those located in the United States and may not maintain the same level of production. Some unethical companies have even tampered with data to gain regulatory approval. In 2008, a Chinese batch of contaminated heparin, a crucial blood thinner for open heart surgery, killed at least 81 patients in America and injured hundreds more. Fortunately, these disasters are rare.

More often than not, we see inconsistencies in the quality of generics and, therefore, in their biological effects. Unlike the single-source brand name drug, generics are produced by more than one company in more than one location. Pharmacies change supplier freely depending on price and / or availability. Even though the concentration of the active chemical remains the same, changing inactive ingredients like fillers, binders, and dyes can cause different reactions when you take the pill.

Following:Don’t let the winter blues get you down, here’s how to stay cheerful in the dark months

What should I do if my generic is not working properly?

There are several options. Ask the pharmacist if a version of the medicine from the previous supplier is still available. Change your pharmacy, which will likely change providers. Some drugs have an “authorized generic” which is exactly the same as the brand name, produced by the same company and factory, but sold without the brand name. It is more expensive than other generics, but has quality assurance from the original pharmaceutical company. If you develop a true allergy or severe intolerance to generics, ask your doctor to specify “brand name only” on the prescription, although this may require passing certain hurdles for insurance to pay for it.

Usually we don’t look twice at the pill bottle after filling a prescription. But as we strive to become more informed healthcare consumers, we hope this generic drug information will encourage you to take a closer look, and perhaps say “Yes” when the pharmacy cashier tells you. ask if you have any questions for the pharmacist about your medicine.

Qing Yang and Kevin Parker are a married couple living in Springfield. Dr. Yang received her medical degree from Yale University School of Medicine and completed her residency at Massachusetts General Hospital. She is an anesthesiologist at HSHS Medical Group. Parker has helped formulate and administer public policy in various cities and state governments across the country. He was previously the Group Information Director for Education at the Illinois Department of Innovation and Technology. This column is not intended to be a substitute for professional medical advice, diagnosis or treatment. Opinions are those of the authors and do not represent the views of their employers.

Generic drugs

Generic Drugs Authorized “Insufficient” to Improve Affordability of Medicare Part D

by Joan J. Dean on October 20, 2021

20 October 2021

2 minutes to read

Source / Disclosures

Published by:

Disclosures: The authors do not report any relevant financial disclosures.

Generic drugs licensed for insulin and direct-acting antiviral agents may reduce out-of-pocket expenses for patients, but are unlikely to save money for Part D plans or Medicare, according to the data.

“Compared to brand name drugs, authorized generic versions of direct-acting antiviral agents for hepatitis C and insulin are said to have resulted in lower out-of-pocket expenses for Medicare beneficiaries.” Stacie B. Dusetzina, PhD, associate professor of health policy and Ingram associate professor of cancer research at Vanderbilt University School of Medicine in Nashville, Tennessee, and colleagues wrote in JAMA Internal Medicine. “However, coverage for authorized generic drugs was limited for some Part D beneficiaries, with many beneficiaries covered by plans covering only brand name drugs. For Part D plan sponsors, this decision likely reflects rational economic behavior, as the net prices (after rebates) of brand name drugs in these classes may be similar to or lower than the net prices of authorized generic drugs.

Various colorful pills — *Source: Adobe Stock*

As Healio previously reported, manufacturers of insulin and direct-acting antiviral agents for the treatment of hepatitis C have recently introduced authorized generic alternatives to their patented branded products at a time when brand name drugs faced no immediate threat of generic competition. Authorized generic drugs have list prices at least 50% below the list price of brand name drugs; the announcements followed close scrutiny in Congress on high drug prices.

In a cross-sectional study, Dusetzina and colleagues analyzed data from the Medicare Prescription Drug Plan form and third quarter 2020 pricing information files and Medicare Part D enrollment for September 2020. Researchers assessed the coverage of four branded formulations of direct-acting insulin and antivirals and their authorized generic formulations: sofosbuvir and velpatasvir fixed-combination tablets (Epclusa, Gilead), ledipasvir and sofosbuvir tablets (Harvoni, Gilead), insulin lispro (Humalog, Eli Lilly) and insulin aspart (Novolog, Novo Nordisk).

“We selected these drugs because we believe they are the only ones to have launched generic formulations authorized more than a year before the expected expiration of the patent and have faced no traditional generic competition in the third quarter of 2020. “the researchers wrote.

The main results were the weighted coverage of the formulary by beneficiaries of branded products and authorized generics; disbursements by the beneficiary; and the prepayment plan, manufacturer and Medicare expenses on branded products and authorized generics.

As of the third quarter of 2020, 97% of beneficiaries were on plans that covered only brand name drugs or both brand name drugs and authorized generics. About 3% of beneficiaries were on plans that covered only authorized generic drugs.

The researchers found that the list prices of authorized generic drugs were 67%, 62% and 50% lower than the list prices of Epclusa, Harvoni and each branded insulin product, respectively. “Medicare beneficiaries using licensed generics could save $ 270 per year for 12 vials of Humalog and $ 2,974 for a full treatment of Harvoni,” the researchers wrote.

The plans, however, have limited incentives to encourage the use of authorized generics; discounts for brands likely exceed savings available with authorized generics, especially for beneficiaries whose spending reaches the Medicare Part D coverage gap.

“Ultimately, the availability of licensed generic options for products that do not face traditional generic competition is insufficient to improve affordability for Medicare beneficiaries,” the researchers wrote. “The results of this study suggest that efforts to change Medicare Part D benefits should also ensure that incentives for plans and beneficiaries are properly aligned and that beneficiaries are not paying too much for drugs that are better.” value for their health plan and Medicare program. “

Perspective

Back to the top

David C. Robbins, MD

I appreciate the extraordinary costs of bringing drugs safely to the consumer. I am troubled by the economic burdens faced by people with diabetes who must have constant access to their medications. Insulin, a biologic, costs more to manufacture and safely administer than many generic drugs, but these costs barely explain the sticker shock many underinsured patients face.

As a clinician, I spend an inordinate amount of my time browsing a maze of insurance coverages and ordering less desirable, but more affordable, alternatives for my patients. Denying patients these treatments is often shortsighted. We are forced to use older, less effective drugs at the cost of an increased risk of crippling complications such as blindness and kidney failure. From a stratospheric public health perspective, this is insane and insane. We are reducing the huge costs of future complications rather than focusing on savings from prevention.

I have read many articles on how the supply chain seems to increase the cost of insulin, but still cannot understand the extraordinary prices faced by consumers whose lives depend on these drugs. Too many of my patients reduce their insulin doses, share them with other family members, or skip them altogether.

Generic insulins will never join the $ 4 a month club, but they will provide healthy competition in a protected market and be welcomed by healthcare providers and their patients. Doctors-in-training at most teaching hospitals have little or no experience with cheaper insulins since the hospital formulary comes exclusively with brand name products. I suspect that drug companies are deliberately providing them at very low cost, inadvertently putting the hospital in the position of promoting more expensive drugs since patients are discharged on those same insulins. Newly trained physicians inadvertently become pawns in the high cost of drugs with little [if] any exposure to the promotion and use of lower cost alternatives. Providers and patients should be made aware that cheaper insulin does not necessarily mean less effective diabetes control.

Medicare could be the 800-pound gorilla when it comes to insulin pricing by competitively pricing and having the courage to stand with the consumer rather than the drug companies.

David C. Robbins, MD

Bud and Sally Cray Professor of Diabetes

Director, University of Kansas Diabetes Institute

Disclosures: Robbins claims to own shares in Eli Lilly.

Medical products

Medical Products Supply Chain Weekly Review – October 2021 # 1 | Alston & Bird

by Joan J. Dean on October 15, 2021

Last week, AstraZeneca and Merck filed Emergency Use Authorization (EUA) applications for their COVID-19 drugs. The FDA has provided information to the public on a database repository of genetic variants and associated conditions. The United States, along with 135 other countries, have agreed to an overall minimum tax of 15%. Please see details of these and other supply chain developments below:

On October 5, AstraZeneca filed an EUA application for its COVID-19 long-acting antibody (LAAB) prophylaxis, AZD7442, composed of tixagevimab and cilgavimab. Although the LAAB combination is under investigation for prophylactic and therapeutic purposes, the EUA’s request was for its prophylactic use against symptomatic COVID-19. Two phase III trials have shown a reduction in the relative risk of symptomatic COVID-19 by 77% and 33%. The data suggests that the drug is also effective against variant strains. On October 11, AstraZeneca also released a press release revealing high-level results from another Phase III trial. The trial showed a reduction in the rates of severe COVID-19 or death in the treatment group, compared to the placebo group, in out-of-hospital participants with mild to moderate symptoms.
On October 5, the FDA released a final rule on the De Novo medical device classification process. The rule establishes procedures and criteria for submitting and withdrawing a De Novo application and how the FDA will assess the application. Based on the new rule, the agency updated the following guidance documents:
- The final guidelines “FDA and Industry Actions on De Novo Classification Requests: Effect on FDA Review Clock and Goals” provide sponsors with information on decision points and deadlines that the FDA will meet when reviewing a De Novo application. .
- The final guide “De Novo Classification Process (Evaluation of Automatic Class III Designation)” provides guidance to sponsors whose device is automatically classified as Type III based on a determination that the device was not substantially equivalent to a predicate device via process 510 (k).
- The final guide “Usage Fees and Refunds for De Novo Classification Requests” provides sponsors with information on De Novo classification requests requiring a fee, requests that are exceptions, and the refund process.
On October 7, the FDA’s Center for Devices and Radiological Health released a Description of Public Human Genetic Variant Databases, a repository of genetic variants and related diseases or conditions. The FDA’s goal is to help manufacturers develop tests for these diseases or conditions by providing FDA-recognized databases that contain data and claims, which can be used to support regulatory review of the FDA. The FDA considers the available databases to be scientifically valid.
On October 8, the United States, along with 135 other countries, approved an overall minimum corporate tax rate of 15%. Multinational companies have transferred their business infrastructure and interests to foreign countries with the lowest tax requirements. Countries with a stricter tax code, such as the United States, may benefit. The goal is to keep business interests in their home country and boost local economies.
On October 11, Merck filed an EUA application for its COVID-19 oral antiviral drug, molnupiravir. The request comes after interim results from the Phase III clinical trial demonstrated a positive benefit: severe hospitalization and death rates were reduced in the treatment group. If approved, the drug would be the first oral antiviral drug to treat COVID-19 that patients can take at home.
On October 12, the FDA announced it was withdrawing three guidance documents: “Temporary Policy for the Preparation of Certain Alcohol-Based Hand Sanitizers During Public Health Emergency (COVID-19)”, “Policy for the temporary composition of certain alcohol-based products for the hands Disinfectant products during a public health emergency” and “Temporary policy for the manufacture of alcohol to be incorporated into disinfectant products for the hands based on alcohol during the public health emergency (COVID-19). ”The manufacture of affected products must cease by December 31, 2021 and distribution by March 31, 2022. The agency determined that the urgent need to temporary orders no longer exist as the supply of alcohol-based disinfectants by “traditional” manufacturers can meet demand.

[View source.]

Medical products

FDA awards 11 clinical trial grants to develop new medical products for treatment of rare diseases

by Joan J. Dean on October 14, 2021

For immediate release:: October 14, 2021

Today, the United States Food and Drug Administration announced that it has awarded 11 new research grants for clinical trials, equivalent to more than $ 25 million in funding over the next four years. The FDA’s congressionally-funded Orphan Products Grants program awards these grants to clinical researchers to support the development of medical products for patients with rare diseases.

“Supporting the development and evaluation of new treatments for rare diseases is a critical part of the FDA’s mission,” said Janet Woodcock, Acting Commissioner of the FDA. needs of those suffering from a rare disease.

Grants awarded support clinical studies of products that address unmet needs in rare diseases or conditions or that provide very significant improvements in treatment or diagnosis.

Many of these studies involve children, as young as newborns, including one evaluating the treatment of a rare inherited skin disease known as recessive dystrophic epidermolysis bullosa, or RDEB, a condition that can lead to severe painful blisters and sores that are often disfiguring and fatal. Another study aims to assess early treatment before seizures appear in infants with tuberous sclerosis, which is an inherited disease that can affect various organs and lead to long-term brain development problems. This grant also includes an innovative demonstration project that will use a collaborative approach to evaluate a tool with the potential to improve data accuracy for clinical trials taking place in more than one location.

Some of the new awards fund clinical studies of products for use in brain cancer. More specifically, we will evaluate a new peptide vaccine to treat pediatric brain cancers. The vaccine is designed to be directed specifically at tumor areas of the brain and has the potential to have a significant impact on how these rare and fatal tumors are treated.

“The Orphan Product Development Office strives to identify, review and ultimately fill the gaps that exist within the rare disease drug development community by funding the necessary clinical studies.” and groundbreaking in determining the safety and effectiveness of potential treatment options, ”said Sandra Retzky, DO, JD, MPH, Director of OOPD. “These grants demonstrate the FDA’s commitment to supporting the development of new treatments for patients living with rare diseases.

Here is a complete list of grants in alphabetical order:

Armgo Pharma, INC. (Ardsley, New York); Eugene Marcantonio; Phase 2 study of S48168 (ARM210) for the treatment of catecholaminergic polymorphic ventricular tachycardia type 1 (CPVT1); $ 1 million over two years
Boston Children’s Hospital (Boston, Massachusetts); Mark Puder; RELiZORB Phase 3 Study for the Treatment of Short Bowel Syndrome; $ 2.7 million over four years
Castle Creek Biosciences, LLC (Exton, Pa); Mary Spellman; Phase 3 study of FCX-007 (genetically modified autologous human dermal fibroblasts) for the treatment of recessive dystrophic epidermolysis bullosa; $ 1.8 million over four years
Cincinnati Children’s Hospital Medical Center (Cincinnati, Ohio); Darcy Krueger; Phase 2b study of sirolimus for the prevention of epilepsy in patients with tuberous sclerosis Bourneville; $ 5 million over four years
Cincinnati Children’s Hospital Medical Center; Michael Jordan; Phase 2 study of abatacept for the treatment of common variable immune deficiency associated with interstitial lung disease (ABCVILD); $ 3.1 million over four years
Duke University (Durham, North Carolina); Eric Thompson; Phase 2 study of a peptide vaccine targeting CMV antigen for the treatment of newly diagnosed high-grade pediatric glioma, diffuse intrinsic pontine glioma and recurrent medulloblastoma; $ 1.8 million over four years
Massachusetts General Hospital (Boston, Massachusetts); Amy Dickey; Phase 2 study of oral cimetidine for the treatment of protoporphyria; $ 1.6 million over four years
Mayo Rochester Clinic (Rochester, Minnesota); Sani Kizilbash; Phase 1 study of WSD0922-FU for the treatment of high-grade astrocytoma; $ 1 million over three years
Mayo Rochester Clinic (Rochester, Minnesota); singer Wolfgang; Phase 2 study of autologous mesenchymal stem cells administered intrathecally for the treatment of multisystem atrophy; $ 3.2 million over four years
Reveragen Biopharma, Inc .; Eric Hoffman; Phase 2a study of vamorolone for the treatment of Becker’s muscular dystrophy; $ 1.2 million over two years
University of Florida (Gainesville, Florida); Peter Stacpoole; Phase 2A trial of dichloroacetate for the treatment of glioblastoma multiforme; $ 2.5 million over four years

As challenges and rising costs have continued this year for clinical trials due to the COVID-19 pandemic, the FDA remains committed to supporting rare disease research by providing existing recipients with additional funding. These resources allow ongoing studies to take the necessary steps to allow their research to continue and to ensure the safety of study participants, maintain compliance with good clinical practice, and minimize risk to the patient. integrity of tests.

Related information

###

master key

The FDA, an agency of the U.S. Department of Health and Human Services, protects public health by ensuring the safety, efficacy, and safety of drugs, vaccines, and other biologicals for human and veterinary use, as well as medical devices. . The agency is also responsible for the safety and security of our country’s food supply, cosmetics, dietary supplements, products that emit electronic radiation, and the regulation of tobacco products.

Generic drugs

Generic Drugs Market Growth of USD 138.90 billion from 2021 to 2025 | Technavio

by Joan J. Dean on October 8, 2021

Read our free sample report to make the most of future growth opportunities.

The Generic Drugs Market report offers a comprehensive analysis of the strategies adopted by the vendors and the trends, drivers and challenges affecting the market size. The report identifies the low cost alternatives as one of the major growth factors of the market. The advent of RPA, the increase in mergers and acquisitions, and hospital-owned generics will be some of the market trends over the next few years.

The generic drugs market covers the following areas:

Sizing of the generic drug market
Generic Drugs Market Forecast
Generic Drugs Market Analysis

Companies mentioned

Amgen Inc.
Dr. Reddys Laboratories Ltd.
Fresenius SE and Cie KGaA
Merck et Cie Inc.
Novartis AG
Pfizer Inc.
Sanofi SA
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Viatris inc.

Subscribe to our “Lite Package” billed annually at 3000 USD to view 3 reports per month and download 3 reports per year.

Associated reports:

Lung Cancer Therapeutics Market by Type and Geography – Forecast and Analysis 2021-2025: The lung cancer treatment market has the potential to grow by $ 6.79 billion from 2021 to 2025. Download a free sample exclusive report
Interstitial Cystitis Drugs Market by Type and Geography – Forecast and Analysis 2021-2025: The market for interstitial cystitis drugs has the potential to grow by $ 283.95 million from 2021 to 2025. Download a free sample report

Scope of the generic drug market
Cover of the report	Details
Page number	120
Year of reference	2020
Forecast period	2021-2025
Growth dynamics and CAGR	Accelerate to a CAGR of 6.33%
Market growth 2021-2025	$ 138.90 billion
Market structure	Fragmented
Annual growth (%)	5.95
Regional analysis	North America, Europe, Asia and ROW
Efficient contribution to the market	North America at 39%
Main consumer countries	United States, Germany, China, Japan and United Kingdom
Competitive landscape	Leading companies, competitive strategies, reach of consumer engagement
Profiled companies	Amgen Inc., Dr. Reddys Laboratories Ltd., Fresenius SE and Co. KGaA, Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. and Viatris Inc..
Market dynamics	Parent Market Analysis, Market Growth Drivers and Obstacles, Analysis of Fast Growing and Slow Growing Segments, Impact of COVID 19 and Future Consumer Dynamics, Analysis of Market Conditions for the Forecast Period,
Customization	If our report didn’t include the data you’re looking for, you can reach out to our analysts and customize the segments.

About Us
Technavio is one of the world’s leading technology research and consulting companies. Their research and analysis focuses on emerging market trends and provides actionable insights to help companies identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialist analysts, Technavio’s report library includes over 17,000 and more reports, spanning 800 technologies, spanning 50 countries. Their customer base consists of companies of all sizes, including more than 100 Fortune 500 companies. This growing customer base relies on Technavio’s comprehensive coverage, in-depth research and actionable market intelligence to identify opportunities in existing markets. and potentials and assess their competitive positions in changing market scenarios.

Contact
Technavio research
Jesse maida
Communication and Marketing Officer
United States: +1 844 364 1100
United Kingdom: +44 203 893 3200
E-mail: [email protected]
Website: www.technavio.com/

SOURCE Technavio

Medical products

Heritage Cannabis announces supply agreements and the first shipment of Opticann medical products to Australia

by Joan J. Dean on October 4, 2021

TORONTO – (COMMERCIAL THREAD) – Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) (“Heritage” or the “Company”), is pleased to announce that its subsidiary Opticann has signed two supply agreements with two well-established Australian companies for the supply of products based on medical cannabis. The first shipment of medical cannabis CBD / CBDA filmstrips totaling $ 60,000 has recently been completed.

As previously announced, Heritage has a limited exclusive agreement with IntelGenx Corp. (“IntelGenx”) (TSX V: IGX) (OTCQB: IGXT) for CBD film products based on IntelGenx VersaFilm® technology for the Canadian and Australian markets. In accordance with the agreement, Heritage is supplying the CBD raw material for the manufacture of IntelGenx film and the supply in Canada and Australia for distribution by Heritage.

Umar Syed, President of the Medical Division of Heritage, said: “Australia is an important and rapidly growing medical market as it is set to grow at over 30% CAGR by 2028 according to Grand View Research. Our Australian distribution partners have been carefully selected for their ability to develop the market for CBD products and monitor the evolution of TGA regulations, including a possible S3 classification which allows the distribution of over-the-counter CBD products. Our proprietary, Quick Dissolving Sublingual CBD Film Strips are unique (CB4 Control Film Strips in Canada) to provide medical patients with a rapid onset and maximum bioavailability of CBD compared to oral products. We are delighted to have completed our first shipments to Australia and plan to add additional products in the future. ”

“As we continue to develop our market and the distribution of our brand in Canada, it is important for us to monitor and act in new markets with a strategic approach in order to capitalize on new market opportunities,” said David Schwede, CEO of Heritage. “By partnering with these well-established companies in Australia, we can leverage their local knowledge and expertise, while minimizing the costs and risks of entering new markets. ”

The CBD filmstrips are produced at the IntelGenx manufacturing facility under Canadian GPP conditions and will be registered as a product for sale with the Therapeutic Goods Administration of the Australian Department of Health as medicinal cannabis.

About Opticann

Opticann’s CB4 medical cannabis product line is based on trusted pharmaceutical technology platforms that are optimized for the efficient delivery of cannabinoids – for maximum effect and to minimize unwanted effects.

Opticann’s patented and proprietary products are based on innovative pharmaceutical technology that delivers the best results consistently, safely, and in convenient dosage forms (capsules, sublingual and topical filmstrips). These dosage forms are tested and optimized to provide active ingredients for effective results. Opticann products also contain the highest quality ingredients and are rigorously tested for consistency.

About heritage

Heritage Cannabis is a leading cannabis company providing innovative products to the legal medical and recreational cannabis markets in Canada and the United States, operating out of two licensed manufacturing facilities in Canada. The company has an extensive portfolio of high-quality cannabis products under the brands Purefarma, Pura Vida, RAD, Premium 5, feelgood, CB4 medical product suite in Canada and ArthroCBD in the United States.

ON BEHALF OF THE BOARD OF DIRECTORS OF HERITAGE CANNABIS HOLDINGS CORP.

“David Schwede”

David Schwede

CEO

The Canadian Securities Exchange accepts no responsibility for the adequacy or accuracy of this release.